Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M829Revenue $M37.1Net Margin (%)-126.2Altman Z-Score10.6
Enterprise Value $M367EPS $-0.4Operating Margin %-154.3Piotroski F-Score4
P/E(ttm)--Beneish M-Score256Pre-tax Margin (%)-126.2Higher ROA y-yY
Price/Book1.910-y EBITDA Growth Rate %-33.0Quick Ratio9.4Cash flow > EarningsY
Price/Sales20.55-y EBITDA Growth Rate %-3.2Current Ratio9.4Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-16.6Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-18.2Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M137ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with ACHN

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
Current Price Change from Average Comment Current Shares
ACHNFirst Eagle Investment 2014-03-31 Sold Out -0.01%$3.08 - $4.2
$ 6.0773%Sold Out0
ACHNFirst Eagle Investment 2013-12-31 Buy 0.01%$2.43 - $3.46
$ 6.07109%New holding600,000
ACHNGeorge Soros 2012-06-30 Sold Out -0.04%$5.94 - $10.95
$ 6.07-17%Sold Out0
ACHNGeorge Soros 2012-03-31 Reduce-0.09%$7.71 - $12.375
$ 6.07-37%Reduce -50.00%250,000
ACHNGeorge Soros 2011-12-31 Add0.16%$4.01 - $8
$ 6.07-1%Add 2132.14%500,000
ACHNGeorge Soros 2011-09-30 Buy $4.63 - $8.31
$ 6.07-5%New holding22,400
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ACHN is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!

ACHN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Apelian DavidChief Medical Officer 2015-12-30Sell10,000$10.5-42.19view
Fenton Mary KayCFO 2015-12-28Sell43,500$10.08-39.78view
VITULLO NICOLEDirector 2015-11-11Sell550,000$10.17-40.31view
VITULLO NICOLEDirector 2015-09-25Sell9,310$8.22-26.16view
VITULLO NICOLEDirector 2015-08-14Sell37,843$7.51-19.17view
Fenton Mary KayEVP and CFO 2015-01-23Sell13,125$16-62.06view
Deshpande MilindPresident and CEO 2015-01-21Sell100,000$15-59.53view
RA CAPITAL MANAGEMENT, LLC 2014-09-30Sell1,332,014$10.2-40.49view
RA CAPITAL MANAGEMENT, LLC10% Owner 2014-09-26Sell2,372,915$11.17-45.66view
RA CAPITAL MANAGEMENT, LLC10% Owner 2014-09-23Sell2,595,071$11.29-46.24view

Quarterly/Annual Reports about ACHN:

    News about ACHN:

    Articles On GuruFocus.com
    UBS and JMP Securities Downgrade Achillion Pharmaceuticals Inc.(ACHN) Following Johnson & Johnson (J May 21 2015 
    Dycom Industries (DY) Surpasses Estimates; Achillion Pharma (ACHN) Inks Mega-Deal with Janssen May 20 2015 
    Gilead Experiencing Bumpy Ride Despite Strong Fundamentals Apr 03 2015 
    Achillion Pharmaceuticals Stock Soars Following Successful Mid-Stage Hep C Drug Combo Trial Feb 10 2015 
    Hall of Fame/ Hall of Shame: The Best and Worst Recommendations of 2014 Jan 09 2015 
    Weekly CEO Sells Highlight: Achillion Pharmaceutical Inc, Protective Life Corp, Host Hotels & Resort Aug 25 2014 
    Top 4 Insider Buys of Last Week Jun 10 2013 
    Weekly CEO Sells Highlight: Achillion Pharmaceuticals Inc, Monster Beverage Corp, CarMax Inc, and Im Jan 23 2012 
    Weekly CEO Sells Highlight: UNH, LRY, ACHN, RPM Jan 16 2012 
    Achillion Pharmaceuticals Inc. Reports Operating Results (10-Q) Oct 27 2010 

    More From Other Websites
    Achillion Begins Study on First Complement Factor D Inhibitor Feb 12 2016
    6:06 am Achillion Pharma initiates phase 1 study of ACH-4471, first orally-administered small... Feb 11 2016
    Achillion Initiates Phase 1 Study of ACH-4471, First Orally-Administered Small Molecule Complement... Feb 11 2016
    Early Briefing on Biotechnology Stocks -- Achillion Pharma, CTI BioPharma, Inovio Pharma, and Keryx... Feb 10 2016
    Achillion to Present at the Leerink Partners 5th Annual Global Healthcare Conference Feb 08 2016
    Achillion Announces Appointments of Martha Manning as General Counsel and Amy Jennings as Head of... Feb 03 2016
    Achillion Pharma downgraded by Leerink Partners Jan 29 2016
    Zacks.com featured expert Kevin Matras highlights: Achillion Pharmaceuticals, Opko Health, Global... Jan 27 2016
    A Company's First Profit Can Mean Big Profits to Investors Jan 26 2016
    Bulls are playing for Achillion rebound Jan 15 2016
    Achillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : January 8,... Jan 08 2016
    Achillion Appoints Dr. Joel Barrish as Chief Scientific Officer Jan 04 2016
    Achillion Appoints Dr. Joel Barrish as Chief Scientific Officer Jan 04 2016
    4 stocks to watch Dec 31 2015
    Achillion (ACHN): Moving Average Crossover Alert Dec 31 2015
    Unusual activity in AAL, ACHN Dec 30 2015
    Bristol-Myers Inks Deal to Sell HIV Pipeline to ViiV Healthcare Dec 21 2015
    Strength Seen in Sequenom (SQNM): Stock Jumps 5% in Session Dec 21 2015
    Today's Market Driven by Key Factors -- Research on Tumi Holdings, Meritor, Achillion... Dec 21 2015

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)